TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025

TuHURA Biosciences, Inc./NV

Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.
Kineta acquisition accounted for as business combination; TuHURA as acquirer with 92.4% ownership post-merger.
Pro forma adjustments eliminate pre-merger intercompany transactions and financing costs.
TuHURA advancing Kineta's VISTA-101 trial; REM-001 study underway with CVR milestone by Dec 31, 2025.
Historical financials of TuHURA remain the consolidated financial statements post-merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.